Home / Transcripts / Aarti Drugs Limited (524348) · August 3, 2026

Aarti Drugs Limited (524348) Earnings Call Transcript

August 3, 2026

BSE Limited IN Health Care Pharmaceuticals earnings 44 min

Earnings Call Speaker Segments

Operator operator
#1

Ladies and gentlemen, good day, and welcome to the Q1 FY 2027 earnings conference call for Aarti Drugs Limited. <<operator_script>> Before we start, here's a brief disclaimer. This call includes forward-looking statements regarding the company, and those are based on what the company believes, its opinions, and its expectations as of the date of this call. Such statements do not guarantee future performance and carry risks and uncertainties that are hard to predict. I'll now turn the conference over to Mr. Adhish Patil, COO and CFO of Aarti Drugs Limited. Thank you, and over to you, Mr. Patil.

Adhish P. Patil executive
#2

Good morning, everyone, and thanks for being with us today for the Aarti Drugs Q1 FY 2027 earnings discussion. With me today is Mr. Harshit Savla, Joint Managing Director.

Harshit Savla executive
#3

Morning, everyone.

Adhish P. Patil executive
#4

Mr. Harit Shah, who serves as Whole-Time Director, and Mr. Vishwa Savla, the Managing Director of Pinnacle Life Science Private Limited, together with our —

Harit Shah executive
#5

Morning, everyone.

Adhish P. Patil executive
#6

— alongside our Investor Relations Advisors, SGA. We trust you've had a chance to review the financial results and investor presentation for the quarter ended 30th June 2026, both of which have been filed with the stock exchanges and can also be accessed on our website. Before we get into the quarterly performance, I'd like to start with some context on the operating environment we saw during the quarter. The first quarter of FY 2027 was again shaped by a dynamic global landscape. Geopolitical developments — in particular, the ongoing conflict in West Asia — continued to be a significant factor weighing on international trade, logistics, and supply chains. The industry also kept seeing elevated freight costs on certain routes, longer procurement cycles in a few regions, and greater volatility in raw material pricing. At the same time, these developments gave rise to a favorable pricing environment across several API products. As availability tightened in certain markets and customers put priority on supply reliability, API prices moved upward across the industry. That translated into significantly better realizations for us during the quarter. While disruptions like these can often breed uncertainty, they also underscore how important it is to be a dependable and integrated manufacturing partner. Customers today are increasingly looking past pricing alone — they're placing greater emphasis on supply security, manufacturing consistency, and long-term partnerships.

Adhish P. Patil executive
#7

These are areas in which Aarti Drugs has developed robust capabilities across multiple years, and we think that leaves us well placed to seize opportunities as the market evolves. What stands out as especially encouraging is that, even with the external environment proving difficult, our operations stayed entirely stable for the whole quarter. We encountered no interruptions to production, no shortages of materials, and no supply-related stoppages. Every one of our manufacturing facilities kept running efficiently, which allowed us to fulfill customer commitments in domestic and international markets alike with no meaningful delays. That operational resilience stems directly from the investments we have made over the years to strengthen our manufacturing footprint, broaden our backward integration capabilities, and keep inventory and procurement practices disciplined. Turning to business performance, I am happy to report that we got the financial year off to a strong start. Results for the quarter came from a healthy mix of better API realizations and volume growth across key products. Demand stayed healthy throughout the API and spec chem portfolio, backed by strong consumption in key therapeutic categories and continued traction in domestic and international markets. Our export business kept performing well as customers increasingly looked for reliable, compliant suppliers able to guarantee uninterrupted deliveries. We also saw steady demand across our domestic formulation business.

Adhish P. Patil executive
#8

Just as importantly, our emphasis on optimizing costs and achieving manufacturing efficiencies kept producing favorable outcomes, and we saw EBITDA margin gains during Q1 FY 2027. That margin growth occurred even with persistent strain from increased raw material prices and higher freight costs, which underscores how resilient our operating models are. Our record on regulatory matters also keeps reinforcing our competitive standing. Approvals from top global regulatory bodies, such as the U.S. FDA and U.K. regulatory agencies, remain in place at our manufacturing facilities. Such approvals do more than confirm our quality systems and manufacturing standards — they also let us reinforce our footprint in regulated markets over the long run. Our manufacturing expansion strategy is another area where steady progress continues. In Q1 FY 2027, planned ramp-up carried on at our Sayakha facility, which ran at close to 65% utilization. For us, this facility remains a strategic investment of real importance. Beyond contributing additional manufacturing capacity, Sayakha bolsters our backward integration capabilities, improves supply chain reliability, and gives us tighter control over key intermediates, particularly for the antidiabetic segment. Once resolved, and as utilization levels keep rising, we anticipate that the facility will add further to operational efficiency and to margin improvement over the long term. In addition to Sayakha, we are likewise maintaining our investments in growing our formulation business.

Adhish P. Patil executive
#9

At the Baddi facility, our brownfield expansion on the adjacent land parcel is moving forward according to plan. When finished, we expect this project to almost double the total capacity we have for manufacturing solid dosage forms. This expansion fits with our long-term strategy of strengthening the formulations business, boosting manufacturing flexibility, and adding capacity that supports future growth opportunities in both regulated domestic and export markets. On the whole, our approach to capital expenditure stays disciplined and focused on growth. Each investment we make is guided by a clear focus on enhancing competitiveness, improving operational efficiency, supporting backward integration, and creating long-term shareholder value. We remain confident that these investments will lay a strong foundation for sustainable growth in the years ahead. Moving to the consolidated financial highlights: Q1 FY ’27 revenue came in at INR 703.6 crores, versus INR590.8 crores in Q1 FY ’26, which works out to 19% growth year-on-year. EBITDA was INR96.9 crores against INR74.7 crores in Q1 FY ’26, up 30% year-on-year. The EBITDA margin was 13.8%, an expansion of 120 basis points year-on-year. PBT was INR69.2 crores compared with INR51.1 crores, a rise of 35% year-on-year. The PBT margin was 9.9%, an expansion of 120 basis points year-on-year. Tax came to INR50.1 crores, as against INR54 crores in Q1 FY ’26.

Adhish P. Patil executive
#10

When you look at Q1 FY ’26 tax PAT, it contains a principal tax refund of INR15 crores. If you take that out, PAT growth would have been 29% year-on-year. Turning to the standalone business highlights for Q1 FY ’27, revenue came in at INR627.6 crores, compared with INR521.3 crores in Q1 FY ’26, which is a 20% year-on-year increase. The standalone business accounted for roughly 89% of consolidated revenue. Domestic sales made up 68% of standalone revenue, while exports accounted for 32%. Domestic revenue rose 25% year-on-year, and export revenue was up 12% year-on-year. Inside the API business, the antibiotic therapeutic category accounted for 35%, antiprotozoan about 18.5%, anti-inflammatory 11.9%, anti-diabetic 18.2%, antifungal 10.2%, and the remainder was roughly 6.1% of total API sales. Now for the formulation segment highlights. Formulation revenue was INR81.6 crore, versus INR75.8 crore in Q1 FY 2026, an 8% year-on-year gain. Exports represented about 74% of that revenue. With that, I would now like to open the floor for questions.

Operator operator
#11

Thanks. At this point we'll open it up for questions. <<operator_script>> Our first question is from Avnish Burman at Vaikarya Funds. Go ahead. Mr. Burman, go ahead.

Avnish Burman analyst
#12

Is my voice coming through?

Adhish P. Patil executive
#13

Yes.

Avnish Burman analyst
#14

Hello? Hello, is this coming through?

Adhish P. Patil executive
#15

Yes, we’re able to hear you.

Operator operator
#16

Yes, please proceed.

Avnish Burman analyst
#17

Yeah, Adhish, I was hoping you could help me get a handle on how metformin realizations have trended — if you could just give some indication of that, and how they've moved both quarter over quarter and year over year?

Adhish P. Patil executive
#18

Yeah. Harit, do you want to take that question?

Harit Shah executive
#19

Thanks. Yeah. What are you referring to, sir — demand, or the price for it?

Avnish Burman analyst
#20

No, it's the price movement on metformin.

Harit Shah executive
#21

On pricing movement, it's risen roughly 15%-20% versus before the war. Approximately 20%.

Adhish P. Patil executive
#22

Yes, Avaneesh. In the case of metformin, the year-over-year increase has been pretty dramatic — very high. The biggest jump, though, happened when the war began, around March and April. As Harit mentioned, it remains above where it was previously even at this point, though it has come down somewhat from the March and April price level.

Avnish Burman analyst
#23

All right, that's clear. And Adhish, could you just help me grasp this — by integrating backward in the product, you'll always have a bit of an edge over the competition. How do you intend to leverage that toward your ambition, say, of gaining market share? Since from what I gather, this is a reasonably mature molecule. Growth for this product worldwide wouldn't be especially high. Yet you have aspirations to expand considerably faster than the industry's growth. So how do you — I mean, once that backward integration is running smoothly, what are the plans?

Adhish P. Patil executive
#24

Right. At present, our capacity for metformin stands at roughly 1,400 tons each month. And we're already running it somewhere in the mid-eighties, you could say. We also expect demand for our metformin to rise quite substantially going forward, thanks to the growing number of approvals we're receiving. Already we have

Avnish Burman analyst
#25

Right, no — what I was hoping to get clear on was this.

Adhish P. Patil executive
#26

We've already secured EDQM approval for this product, and going forward we're also planning to pursue US FDA approval for metformin. So at present, our plan is to increase metformin capacity from 1,400 tons per month up to approximately 2,200 tons per month, and of that, roughly 500 to 550 tons per month would be US FDA capacity, while the remaining capacity would serve the other market — the non-US FDA market. So moving ahead, we'll need a great deal of support from our backward integration, which we've already completed in Sayakha. That's why we believe the Sayakha facility will remain a very important area where we want to streamline production as quickly as possible and support metformin's growth. So metformin is already expanding worldwide, it's an enormous market, and there's plenty of potential for us to capture additional market share as well.

Avnish Burman analyst
#27

What's your expected timing for supplying the U.S. market — in other words, when might we expect the approval to come through?

Adhish P. Patil executive
#28

Right. So the U.S. DMF has already been filed, so that part isn't a problem. The real issue is the facility, since we're building new capacity of roughly 500-plus tons per month on the same land parcel, at the same location. So it'll take roughly 10 months to 12 months for that capacity to come online, and as soon as it does, we'll file for the US FDA inspection with help from some customers.

Avnish Burman analyst
#29

Right, so the bottom line is that you aren't able to provide the API at all until the facility has its approval. That means the earliest point at which API supplies could take place is 12 months from now.

Adhish P. Patil executive
#30

Right. Right. That’s going to take a minimum of 12 months. As things stand, we already have approval from Europe for that same facility.

Avnish Burman analyst
#31

What volume are you providing to the European market?

Adhish P. Patil executive
#32

Honestly, that's not a big amount. It's really not much — and even Europe remains untapped, although at present we're making attempts with the smaller companies. The main difficulty we've encountered up to now is that a lot of European metformin clients also do business in the U.S. market. As a result, they require a supplier holding both European and US FDA approval. That's chiefly why we're pursuing US FDA approval, since it will unlock for us not just the U.S. market but the enormous European markets too.

Avnish Burman analyst
#33

All right, got it. Thanks a lot. Adhish, congratulations on the role elevation as well — many congratulations.

Adhish P. Patil executive
#34

Thanks. Thanks a lot.

Avnish Burman analyst
#35

Appreciate it. I'll follow up with you.

Operator operator
#36

Thanks. Our next question is from Parth Sodha at Trinetra Asset Management. Please go ahead.

Parth Sodha analyst
#37

Can everyone hear me? Hi there?

Adhish P. Patil executive
#38

Yes.

Operator operator
#39

Right, that's you. Go ahead.

Parth Sodha analyst
#40

Yes. Well, to start with, thanks for giving me the chance. So what I'd like to ask is, would you say the API sector has moved into a lasting recovery period, or would you say it's still too soon to tell?

Adhish P. Patil executive
#41

The issue is the overall picture—just a month ago we believed everything had been streamlined and would return to normal. Yet at this moment, things remain so volatile that making any prediction is difficult. Still, when it comes to the antibiotic, particular therapeutic categories, particular products, demand for those items behaves this way when prices drop. For us, honestly, even with lower prices, provided they hold steady, we can certainly earn attractive margins. At least for our product line, competition from China was never a concern. Naturally, you always encounter a bit of pressure here and there from certain players, on certain products at a given moment, because of inventories too. Those sometimes cause trouble as well. On the whole, what we believe is that the API business—given the sort of product profile we operate within it—is fairly stable; stable in the sense that, at least, Chinese competition does not worry us much.

Parth Sodha analyst
#42

Alright, got it. For my second question: now that the INR600 crore capex has been completed, what asset turnover should we expect, and what revenue contribution, say, over the coming two years to three years?

Adhish P. Patil executive
#43

Okay, so the asset turn coming from the Phase 1 Greenfield facilities sits at roughly about 1.5 times, give or take. Regarding Sayakha, close to 50% of those capacities are being used captively for capital consumption within our anti-diabetic portfolio. So that contributes more to gross margins than it does to revenue itself. That said, the Phase 2 Brownfield capex, which is coming at both of these sites — Sayakha and G-61 in Tarapur — should deliver a much higher asset turn, somewhere around three times, four times, since most of the shared facilities, you know, things like ETPs and so on, are already installed and operating. So that opex and capex has all been spent already. The newer Phase 2 capex will generate higher returns, while the one we just completed will get us to roughly one and a half times.

Parth Sodha analyst
#44

Alright. Understood. Understood. I really appreciate the chance.

Operator operator
#45

Thanks. Our next question is from Rashmi Shetty at Dolat Capital. Rashmi, please go ahead.

Rashmi Shetty analyst
#46

Yeah, thanks for the chance to speak. Adhish, you brought up metformin — you're building new lines over at the Saykha plant, correct? For 500 to 550 tonnes in the U.S.

Adhish P. Patil executive
#47

No, no. So that metformin expansion, it's happening at the same Sarigam facility.

Rashmi Shetty analyst
#48

Alright.

Adhish P. Patil executive
#49

We're already at roughly 1,400 tonnes per month. So we'll be ramping up to about 1,700 tonnes per month — 1,700 to 1,800 tonnes — 1,700 tonnes per month, and for an extra 500 tonnes per month, we'll be building a USFDA block at the same site.

Rashmi Shetty analyst
#50

Same site. All right. So what's the latest on the E-22 facility, the one that already has USFDA approval? At present, how many products do we supply from it, and which markets do they go to?

Adhish P. Patil executive
#51

Right now, at our existing USFDA facility, we operate 2 primary manufacturing lines plus a single smaller line dedicated to high-value items. At present, we handle products such as sedatives, antibiotics, and anti-inflammatories, and those are already performing strongly. We anticipate that within 12 months our capacity will become insufficient, since these items are quite large in tonnage terms. So we are also planning what you could call a quasi-greenfield USFDA project on the plot right next door, so it will carry the same API number. That should deliver a capacity increase—roughly slightly more than 2x what we have now. We intend to add 3 additional manufacturing lines at approximately 10-odd tonnes per month apiece; these will be multipurpose lines, allowing us to serve more products. As things stand, about 4 or 5 products are active from the present USFDA plant. Not every one of them ships to the U.S. market, though—a portion also goes to the European market.

Rashmi Shetty analyst
#52

So basically, at the moment we're supplying just the EU markets with all four to five of these products, correct?

Adhish P. Patil executive
#53

Right, right. Yes, yes. So the U.S. market hasn't kicked off yet; business development has already begun the sample approval process. We've also already sent samples out to the customers.

Rashmi Shetty analyst
#54

Alright.

Adhish P. Patil executive
#55

Once their vendor-addition approval comes through, that's when we can begin the supplies.

Rashmi Shetty analyst
#56

Alright. Alright. At the Saykha facility, those Specialty Chemical goods — in your greenfield plant, Specialty Chemical goods get produced as well, correct?

Adhish P. Patil executive
#57

At Saykha, that's correct.

Rashmi Shetty analyst
#58

So Specialty Chemical grew roughly 149%, right? Sales came in at about INR82 crores. Is that mainly down to the new plant coming on stream and us supplying newer products? Basically, how should we think about it for the full year? Will it add meaningfully this year?

Adhish P. Patil executive
#59

Right, so this performance from the first quarter is absolutely going to carry through the coming three quarters. And honestly, we'll be working to make it even better, and to answer what you asked — yes, that's down to the Saykha facility that we've only just brought online.

Rashmi Shetty analyst
#60

And what's the monthly tonnage we've gotten to for this Spec Chem business at the Saykha plant?

Adhish P. Patil executive
#61

Right, so on Saykha — for the methylamine plant, we've already gotten to roughly 65% utilization. A handful of other products are running at lower utilization levels. We're working on improving those. But methylamine is the main gas where we already hit about 64%, 65% during the June quarter.

Rashmi Shetty analyst
#62

So how many tonnes per month does that work out to?

Adhish P. Patil executive
#63

It is — I'll tell you. That figure comes to approximately 60 tonnes per day.

Rashmi Shetty analyst
#64

Alright.

Adhish P. Patil executive
#65

Across the full quarter — the June quarter — the total came to roughly 3,500 tonnes.

Rashmi Shetty analyst
#66

All right, all right. So essentially, for this year, this is going to be the new quarterly run rate for Specialty Chemicals, if you'd like to model that in —

Adhish P. Patil executive
#67

That's right, that's right.

Rashmi Shetty analyst
#68

Right. OK, so about your Tarapur facility — where do things stand right now on the salicylic acid supply?

Adhish P. Patil executive
#69

Right, so we're still waiting on that improvement at the facility. Actually, last quarter we kept salicylic acid output extremely low — across the whole quarter, just 67 tons of salicylic acid were produced. A key reason was that we were awaiting the equipment, which has now arrived and is installed. Its main purpose was to bring raw material costs down further and also enhance the effluent quality from the salicylic acid. On top of that, we've just commissioned the plant for making a salicylic acid derivative, namely methyl salicylate, and a few other salicylates can be produced there too since it's a multipurpose plant. That capacity comes to roughly 354 tons per month. Trial batches have therefore begun. We obtained about five, 10 tons of trial production, and we'll be ramping it up soon. So what we'll be trying to do is produce the salicylic acid, then convert it into the derivatives, and then sell those to the market, because that will cut our losses. Unfortunately, what happened with the anti-dumping duty part is that it got delayed a little bit. The case itself was fine, but the government asked that the injury period should be one year more.

Adhish P. Patil executive
#70

So we’ll probably need to wait another year before the anti-dumping duty is imposed. Still, we’re quite confident it will be applied to salicylic acid. Until then, though, I think the better approach for us is to make the salicylic acid derivative and sell that into the market, since at least that way we’ll try to reach breakeven for that location.

Rashmi Shetty analyst
#71

And broadly speaking, would you say margins on salicylic acid derivatives run higher than they do on the main product?

Adhish P. Patil executive
#72

Okay, so here's what happened: before we began production, salicylic acid on its own carried very strong margins, and the derivatives also had a decent margin. But the thing is, with derivatives you have to spread your bets across four or five products, while with salicylic acid you can capture all of that margin in just one product. So the original plan was to make salicylic acid and supply it to Indian consumers. But after we brought the capacity online, the Chinese players slashed salicylic acid pricing dramatically, mainly to push the competition out — that's the primary aim. Because of that, salicylates turned more attractive than salicylic acid itself thanks to that price drop. At the start it wasn't that way, but as things stand now, salicylates are more profitable than salicylic acid.

Rashmi Shetty analyst
#73

All right, all right. My final question concerns the volume increase and the price increase for this quarter, and also whether you could provide an outlook on those for the three quarters that remain.

Adhish P. Patil executive
#74

Yeah. So in terms of volume growth — the bulk of that increase has come from this segment. At the overall company level, we still managed aggregate volume growth of roughly 3.5% across both domestic and local markets. However, the majority of the growth in the June quarter was driven by price growth. And the primary reason for that is that certain price hikes happened because raw material prices rose on account of the U.S.-Iran war. And with such a sharp jump in prices, typically what happens is that formulation purchasers hold back from buying too much. They keep their stock at a minimum since the prices are very high. And that definitely has an impact on the quantity of, you could say, demand. The quantity of sales declines in such a scenario. But even so, we were able to achieve 3.5% growth, though it was mainly driven by price. As of now, pricing has eased out compared with the months of March and April. So it came down gradually from April, May, and now. But the prices are still high because the war has restarted again and we are not sure how long it will now get stretched.

Rashmi Shetty analyst
#75

How much did pricing grow year over year in absolute terms?

Adhish P. Patil executive
#76

Looking at it year over year, across the aggregate, we observed aggregate growth of roughly 16% to 17%.

Rashmi Shetty analyst
#77

All right. Yet your sense is that this won't hold up over time, correct? Since from a structural standpoint, there's no relief when it comes to the pressure on pricing.

Adhish P. Patil executive
#78

At the moment, the pressure remains, but as the war situation settles and everything loosens up, then once raw material prices fall, selling prices will likely drop as well.

Rashmi Shetty analyst
#79

All right, all right. Then for the other three quarters, what's the outlook on volume growth and price growth? I mean, how do you view it — any guess or estimate?

Adhish P. Patil executive
#80

To be honest, we expect volume growth to be significantly stronger than what we saw in the June quarter, since prices jumped abruptly during that quarter. As I mentioned, that spike hurt demand. Yet if prices remain elevated for an extended stretch, demand ought to recover. Demand should return once inventory levels further down the value chain come down. Export demand will not be affected much. What we have seen in the past—looking back three or four years—is that it is mainly domestic demand: in very high price scenarios, certain product categories, primarily antibiotics and a few antidiarrheals, come under demand pressure.

Rashmi Shetty analyst
#81

All right, understood. Thanks, and congratulations on the new position.

Adhish P. Patil executive
#82

Thanks. Thanks a lot.

Operator operator
#83

Thanks. The next question is from Sunil Desai at Turtle Capital. <<operator_script>> Mr. Desai, you're up.

Sunil Desai analyst
#84

Yes. Morning, Adhish. Can you hear me okay?

Adhish P. Patil executive
#85

Yes.

Sunil Desai analyst
#86

Yeah, so Adhish, the first thing I want to ask about is what you mentioned regarding volatility on the pricing side — that realization piece. Now, I think even before this price increase came along, our eventual aim was to get to 14%, 15% EBITDA margin in due course. So once realization comes down, once the volatility settles and both realization and RM come down, do you think we're on track to hit 15% margin perhaps by the end of this year, or is that a longer journey?

Adhish P. Patil executive
#87

Yes. In this quarter as well, we recorded certain write-offs related to aging capital CWIP, yet by doing so, we had crossed roughly 14% EBITDA margin during Q1 too on a consolidated basis. So 14% is pretty achievable. We're nearly there. Nearly there. Now, when utilization at the two main greenfield projects that we have set up improves, then 15% definitely ought to be very easy. When the salicylic acid plant gets on track, that drag on the overall P&L will come down. So above 14%, we're already nearly there.

Sunil Desai analyst
#88

That realization might not hold steady at the same level, correct? So it's going to come down.

Adhish P. Patil executive
#89

Okay.

Sunil Desai analyst
#90

So that would suggest the 14% we're seeing in Q1 might eventually come down as prices fall. Is that a reasonable way to look at it?

Adhish P. Patil executive
#91

For the near term, yes. But then what happens is that, ideally, once the pricing rate comes down, volume growth should pick up, since our volumes in the March quarter were significantly higher than in the June quarter. So on the whole, we're nearly there. I'd say it again: we're nearly there. During the December and March quarters, the key factor was that our CICA plant wasn't running at full capacity either. Utilization stood considerably lower — 30% and 40%, respectively. And this quarter is the first one in which utilization exceeded 60%. So that's another reason the EBITDA margins have risen somewhat.

Sunil Desai analyst
#92

Understood. On your second question, Adhish: we've invested heavily in capital expenditure over the past two years across a range of products. Given that, should our target of double-digit volume growth — perhaps 15% — serve as the baseline? After all, we were already achieving 7% to 8% volume growth even in the absence of that capex, correct? So with all these new products and the new capex now in the picture, are we targeting something like 15% volume growth, or do you see it landing nearer to high single digits or low double digits?

Adhish P. Patil executive
#93

Yeah, so here's the thing: over the next two years, we're in a really strong position to hit that 10% to 15% volume growth. Right now, even if I just take salicylic acid capacity at 600 tons per month, we're running at roughly 70% utilization, and that's mainly because of that project. So there's plenty of room with existing products, plus some in the CICA facility and a lot in the salicylic facility. So the capacity is there. So hitting 10% to 15% volume growth over the next two years shouldn't be an issue. The only challenge is how quickly we can streamline the salicylic acid and the derivative side.

Sunil Desai analyst
#94

All right. So on the salicylic acid side — suppose that until the anti-dumping duty takes effect, in the next worst case, maybe even the derivative piece doesn't pick up — then absent that, can we still reach that 10%, 12% volume growth?

Adhish P. Patil executive
#95

Yeah. We should still be able to hit 10%.

Sunil Desai analyst
#96

Understood. And it would help if you could walk us through the mix — how it has shifted over time between the regulated and unregulated market, roughly speaking. Europe, I believe, was fairly small for us, and the U.S. was basically non-existent, and those are typically better realization markets. So tell us how that has evolved for us, and how you expect it to develop going forward, now that the U.S. FDA matter — at least for one plant — is resolved?

Adhish P. Patil executive
#97

Yes. Yes, that's a major priority for us moving forward — how do we grow sales in regulated markets. Getting U.S. FDA approval for the API facility after a wait of 10 years was definitely significant. Now that this scope has opened up for us, not just for the U.S. but for Europe as well, plus we received around — for European markets for nine products. And as I mentioned earlier, we have already filed to shift some of them to a larger WHO-type GMP plant, which will be converted into an EDQM approved plant. So our cost structure will come down, pricing will rise. So there will be margin expansion. Plus we'll get additional volumes too because of the European markets. And besides that, we have also received good — all regulatory approvals for our formulation business as well. We obtained U.S. FDA approval for the oncology. We also received European approval for the oral solid dosage. And there too we are filing a lot for regulated markets. And formulation has already shown that more than 70% of our formulation business is now done in export markets.

Adhish P. Patil executive
#98

We’re also going after regulated markets in that division—both on the formulation side and with APIs. That said, I’d note that today’s sales still don’t show the profitability that will come through the regulated market. It remains in the business development phase. We’ve had some wins, but as it grows—once the pie becomes meaningful—then it meaningfully reflects the overall EBITDA margins of the company.

Sunil Desai analyst
#99

Understood, thanks. That covers everything.

Operator operator
#100

Thanks. Our next question is from Sajal Kapoor of Antifragile Thinking. Go ahead, Mr. Kapoor. Please go ahead.

Sajal Kapoor analyst
#101

Thanks for giving me the chance to speak. Yeah, hello. Yeah, hello. I can hear you fine. So the question is this: what portion of Sayakha’s advantage can be seen in revenue right now? And what portion remains unseen, since it substitutes for intermediates that used to be sourced from outside?

Adhish P. Patil executive
#102

Sure. I'd put it this way: in the last quarter — the June quarter — we still had to source somewhere around 60%, 70% from outside. But that share has already dropped sharply this quarter. As we move through the September quarter and then into the December quarter, I think hopefully about 80%, 90% of captive consumption will come through the Sayakha plant. We'll always need to retain roughly 10% external supplies for diversification purposes, but yes, in the September quarter and the December quarter, captive consumption will rise sharply compared with the June quarter.

Sajal Kapoor analyst
#103

The real point here is that using our own captive supply ought to lift our gross margins, correct — since it’s a —

Adhish P. Patil executive
#104

Correct.

Sajal Kapoor analyst
#105

On backward integration: it hands us greater control over the value chain, and beyond that, in the customer's view, it makes us a more secure source, since we aren't depending on outside parties. Sure, 10% is acceptable when it comes to diversification. But how do you see gross margins as utilization rises past 65% — where we stand today — to, say, something nearer 90%?

Adhish P. Patil executive
#106

Our expectation is that this ought to contribute roughly another 1% to gross contribution once it reaches the peak level.

Sajal Kapoor analyst
#107

Okay, so that gross contribution, when you combine it with improved use of the network, should naturally lift EBITDA margins. I believe the other participant's question followed that same thread — looking at how quickly, or when, we can return to 15%. So taken together, those two factors — better gross margins and better utilization — ought to produce significantly stronger EBITDA margins. In fact, it could even be a 200 basis point improvement, right?

Adhish P. Patil executive
#108

Yeah, under the present circumstances, that's right. But what took place in the June quarter was that, owing to those ammonia shortages along with shortages of derivative compounds, pricing rose rather sharply across this product chain. So after things calm down, we'll have to see whether those 200 basis points materialize or not.

Sajal Kapoor analyst
#109

Alright, that's everything. Thanks very much. Thanks.

Adhish P. Patil executive
#110

Alright, thanks.

Operator operator
#111

Thank you. Ladies and gentlemen, since no more questions remain, that brings the question-and-answer session to a close. At this point, I'd like to pass the conference back to management for their closing remarks.

Adhish P. Patil executive
#112

The mix we have — APIs, formulations, and specialty chemicals — plus the relationships we've built with customers over the years and a wide product range, and the investments we keep making to expand capacity and run operations better, all of that leaves us, in our view, in a strong spot to seize these opportunities and keep up our growth momentum in the years to come. Thanks again for your ongoing support and for the confidence you place in Aarti Drugs. Should you have any more questions, please contact SGA, our Investor Relations Adviser. Thank you very much, and have a great day.

Operator operator
#113

<<operator_signoff>>

Harshit Savla executive
#114

Appreciate it.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Aarti Drugs Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Aarti Drugs Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.